Article Information
History
- April 5, 2022.
Article Versions
- You are currently viewing Version 1 of this article (April 5, 2022 - 19:50).
- View Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Jia-Yuan Zhang1,
- Fiona Hamey1,
- Dominik Trzupek1,
- Marius Mickunas2,
- Mercede Lee1,
- Leila Godfrey1,
- Jennie H.M. Yang2,
- Marcin L Pekalski1,
- Jane Kennet3,
- Frank Waldron-Lynch4,
- Mark Evans5,
- Timothy I. M. Tree2,
- Linda S. Wicker1,†,
- John A. Todd1,† and
- Ricardo C. Ferreira1,†,*
- 1JDRF/Wellcome Diabetes and Inflammation Laboratory, Wellcome Centre for Human Genetics, Nuffield Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom
- 2Department of Immunobiology, King’s College London, School of Immunology and Microbial Sciences, London, United Kingdom
- 3Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, University of Cambridge Addenbrooke’s Hospital, Cambridge, United Kingdom
- 4Vertex Pharmaceuticals, Vertex Cell & Gene Therapies, Boston, Massachusetts, United States of America
- 5National Institute for Health Research, Cambridge Biomedical Research Centre, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom
- ↵*Corresponding author; Email: ricardo.ferreira{at}well.ox.ac.uk
Posted April 05, 2022.
Low-dose IL-2 reduces IL-21+ T cells and induces a long-lived anti-inflammatory gene expression signature inversely modulated in COVID-19 patients
